Robenacoxib Market

Robenacoxib Market Size, Share & Industry Analysis, By Source (Petroleum-Based, Bio-Based), By End-User (Pharmaceuticals & Healthcare, Food & Beverage, Cosmetics & Skincare, Chemical & Polymer Industry), and Forecast Period 2025-2035

The Robenacoxib market is projected to grow at a CAGR of 6.1% from 2025 to 2035, driven by increasing pet ownership, rising prevalence of osteoarthritis and post-operative pain in companion animals, and a growing shift toward selective COX-2 inhibitors for improved safety in veterinary care. Robenacoxib is a nonsteroidal anti-inflammatory drug (NSAID) of the coxib class, acting as a selective cyclooxygenase-2 (COX-2) inhibitor, which provides analgesic, antipyretic, and anti-inflammatory effects with minimal impact on gastrointestinal and renal functions compared to non-selective NSAIDs.

Primarily approved for use in dogs and cats, Robenacoxib is indicated for the treatment of pain and inflammation associated with musculoskeletal disorders and soft tissue surgeries. Its availability in both tablet and injectable formulations enhances dosing flexibility in clinical and home settings. With a favorable safety profile, particularly in feline patients where NSAID use is typically limited, Robenacoxib is becoming a drug of choice in long-term osteoarthritis management and perioperative pain control in veterinary medicine.

North America dominates the Robenacoxib market due to high veterinary care expenditure, widespread awareness of pet wellness, and the early adoption of advanced pain management protocols. Europe follows, supported by stringent animal welfare regulations and expanding use of preventive care. The Asia-Pacific region is projected to grow rapidly due to increasing demand for companion animal healthcare, rising disposable incomes, and growth in veterinary pharmaceuticals. Latin America and Africa also show steady growth, driven by improving access to veterinary drugs and expanding animal health infrastructure.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

Introduction

Overview of Robenacoxib
Key End-Users & Industry Use Cases
Market Scope & Study Objectives

Market Overview

Global Market Size & Growth Trends (Historical & Forecast)
Demand-Supply Dynamics

Segmental Outlook

By Source
Branded Robenacoxib (e.g., Maxalt-MLT)
Generic Robenacoxib
Key End-Use Industries
Ophthalmology Clinics
Hospitals
Retail Pharmacies
Online Pharmacies

Price Analysis

Current Price Trends (Per kg & Per Ton)
Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)

Trade Analysis

Major Exporting & Importing Countries
Trade Volume & Value Statistics
Impact of Trade Regulations & Policies

Regional Analysis

North America (US and Canada)
Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
Rest of the World (Latin America, and Middle East, and Africa)

Competitive Landscape

Top Global Manufacturers & Production Capacity
Company Profiles & Key Developments
Rochem International Inc
HRV Global Life Sciences
Alivira Animal Health
Tianhe Pharmaceutical Co., Ltd.
Manus Aktteva Biopharma LLP
Clearsynth
Anax Laboratories
AFINE CHEMICALS LIMITED
Finetech Industry Limited
LEAP CHEM CO., LTD.
Suzhou Senfeida Chemical Co., Ltd.
Wuhan Topule Biopharmaceutical Co., Ltd.
Henan Fengda Chemical Co., Ltd.
Shanghai Kean Technology Co., Ltd.
Amadis Chemical Company Limited
ChemScene LLC
Santa Cruz Biotechnology
Cayman Chemical
MedChemExpress
Sigma-Aldrich

Regulatory & Compliance Factors

FDA, REACH, and Other Regulatory Frameworks
Environmental & Safety Considerations
Emerging Policies Impacting Market Growth

Conclusion & Strategic Recommendations

Key Takeaways for Stakeholders
Market Entry Strategies

May 28, 2025

What is Robenacoxib?

acoxib is a non-steroidal anti-inflammatory drug (NSAID) of the coxib class, primarily used in veterinary medicine for the treatment of pain and inflammation in cats and dogs. It works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which is involved in the synthesis of prostaglandins that mediate inflammation, pain, and fever. By targeting COX-2 while sparing COX-1, Robenacoxib reduces inflammation with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs. It is commonly prescribed for musculoskeletal disorders, post-operative pain, and osteoarthritis in animals. Robenacoxib is available in oral tablet and injectable forms and is marketed under brand names such as Onsior.

What is the market growth of Robenacoxib?

The global Robenacoxib market is expected to grow at a CAGR of 5.4% from 2025 to 2035, increasing from approximately USD 270 million in 2025 to around USD 460 million by 2035. This growth is driven by rising pet ownership, increasing awareness of animal healthcare, and a growing demand for safer, targeted pain management solutions in veterinary practice. As pet owners seek higher standards of care and longevity for their companion animals, the use of selective COX-2 inhibitors like Robenacoxib is becoming more widespread.

What are the drivers of the Robenacoxib market?

Key drivers of the Robenacoxib market include the global increase in pet adoption, higher spending on companion animal health, and the growing emphasis on veterinary pain management. The drug’s selective COX-2 inhibition provides effective anti-inflammatory relief with fewer gastrointestinal side effects, making it a preferred choice for veterinarians. Additionally, increased surgical procedures and aging pet populations are contributing to the demand for post-operative and chronic pain treatment options. The expansion of veterinary clinics and improved access to animal healthcare in emerging markets also supports market growth.

Who are the key players operating in the Robenacoxib market?

The key player in the Robenacoxib market is Elanco Animal Health, which markets the drug under the brand name Onsior. Elanco holds regulatory approvals in multiple regions, including the United States, Europe, and Asia. Other veterinary pharmaceutical companies that provide complementary or competing NSAIDs include Zoetis, Boehringer Ingelheim Animal Health, Virbac, and Vetoquinol. These companies are focused on expanding their product portfolios and geographical reach in the animal health segment.

Which region will exhibit the fastest growth in the Robenacoxib market?

The Asia-Pacific region is anticipated to exhibit the fastest growth in the Robenacoxib market due to increasing pet adoption rates, rising disposable incomes, and expanding veterinary infrastructure in countries like China, India, and Southeast Asia. North America currently leads the market, driven by high veterinary healthcare standards, strong pet insurance coverage, and robust distribution channels. Europe also maintains a significant share, supported by widespread awareness of animal welfare and stringent regulatory frameworks for veterinary drugs.

$1800/- Single User License
$3600/- Multi User License

Experienced in market research and consulting.
Seasoned professionals with diverse industry knowledge.
Proven track record in delivering valuable insights.
Tailored methodologies for unique client needs.
End-to-end services: market analysis, competitor intelligence, consumer behavior, and strategic recommendations.
Latest tools and tech for data collection, analysis, and visualization.
Embrace of AI and machine learning for deeper insights.
Global capabilities and extensive network.
In-depth understanding of international markets, trends, and regulations.
Dedicated to addressing specific client needs and goals.
Focus on delivering value through efficient research outcomes.

How can we help you?

Reach out to discuss how our team can help your business achieve real results.

Contact Person

Mr. Anurag Tiwari

Call Us

+91-780-304-0404

Mail Us

info@omrglobal.com